

PROGRAM

8:30 a.m.

Welcome coffee

9:00 a.m. - 9:30 a.m.

Official allocutions

- **Frédérique VIDAL**, Higher Education, Research and Innovation's Minister,
- **Yves LEVY**, CEO of Aviesan and Chairman of Inserm, **Marc BONNEVILLE**, CEO of ARIIS

9:30 a.m. - 9:40 a.m.

Introduction of topics

- **Sebastian AMIGORENA**, CNRS, Inserm, Institut Curie, Université Paris Descartes, Paris
- **Alexandre PASSIOUKOV**, VP Head of Translational Medicine, Pierre Fabre

9:40 a.m. - 10:50 a.m.

Session 1 - Biomarkers and responses to therapies

9:40 a.m. - 10:00 a.m. Short talks (5 minutes each)

- Classical biomarkers on tumor cells PD-L1 and beyond - **Frédérique PENAULT-LLORCA**, Centre Jean Perrin, Inserm, Université d'Auvergne, Clermont-Ferrand
- Tertiary Lymphoid Structures: an anti-tumor school for adaptive immune cells and an antibody factory to fight cancer - **Marie-Caroline DIEU-NOSJEAN**, Centre de Recherche des Cordeliers, Inserm, Université Denis Diderot, Université Paris Descartes, UPMC, Paris
- Multivariate responses signatures to Immunotherapies - **Vassili SOUMELIS**, Inserm, Institut Curie, Université Paris Descartes, Paris
- Biomarkers derived from the microenvironment - **Eric TARTOUR**, Inserm, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris

10:00 a.m. - 10:50 a.m. Round-table

- **Jean-Yves BLAY**, Centre Léon Bérard, CNRS, Inserm, Université Claude Bernard, Lyon (**Moderator**)
- **Mike BURBRIDGE**, Head of Translational Oncology, Servier
- **Marielle CHIRON**, Global Oncology Translational Medicine Head, Sanofi
- **Jérôme GALON**, Centre de Recherche des Cordeliers, Inserm, Université Diderot, Université Paris Descartes, Paris
- **Daniel OLIVE**, Centre de Recherche en Cancérologie de Marseille, CNRS, Inserm, Université Aix-Marseille, Marseille
- **Martina PUGLISI**, Sr. Clinical Director, Oncology European Clinical Development /MRL, MSD

10:50 a.m. - 11:20 a.m.

Coffee break

11:20 a.m. - 12:35 p.m.

Session 2 - Next generation in the immuno-oncology field

11:20 a.m. - 11:40 a.m. Short talks (5 minutes each)

- CAR/biospecific antibodies in acute leukemias - **Nicolas BOISSEL**, AP-HP, Hôpital Saint-Louis, Université Paris Diderot, Paris
- Comprehensive study of tumor immune microenvironment to improve anti-cancer therapies - **Nathalie BONNEFOY**, Inserm, Institut de Recherche en Cancérologie de Montpellier, Université de Montpellier
- Therapeutic targeting of immune checkpoint regulation in cancer - **Jean-Jacques FOURNIE**, Centre de Recherche en Cancérologie de Toulouse, CNRS, Inserm, Université Toulouse III Paul Sabatier, Toulouse
- Identification of immunogenic cell death inducers by means of a screening platform - **Guido KROEMER**, Centre de Recherche des Cordeliers, Inserm, Université Denis Diderot, Université Paris Descartes, UPMC, Paris

11:40 a.m. - 12:35 p.m. Round-table

- **Véronique BLANC**, Immuno-Oncology Program Director, Servier
- **Eric BORGES**, Vice President, Cancer Immunology & Immune Modulation, Boehringer Ingelheim
- **Patrice DENEFLÉ**, Translational Research Institute Director, Institut Roche (**Moderator**)
- **François GHIRINGHELLI**, Centre Georges-François Leclerc, CHU de Dijon, Inserm, Université de Bourgogne, Dijon
- **Laure de PARSEVAL**, Clinical Site Head, Translational Clinical Oncology, Novartis
- **Loïc VINCENT**, Head Immunology Partnerships, Takeda Global
- **Eric VIVIER**, Centre d'Immunologie de Marseille-Luminy, CNRS, Inserm, Université d'Aix-Marseille, Marseille

12:35 p.m. - 1:20 p.m.

New models in public-private partnerships in the immuno-oncology field (8 minutes per project)

- RHU PIONeer - **Nathalie VAROQUEAUX**, VP Europe Oncology Medical Head, AstraZeneca & **Fabrice BARLESI**, Centre d'Essais Préoces en Cancérologie de Marseille, AP-HM, Université Aix-Marseille, Marseille
- imCORE Network: New forms of public-private partnerships - **Patrice DENEFLÉ**, Translational Research Institute Director, Institut Roche
- MOSCATO Program - **Laurent DEBUSSCHE**, Head of Oncology Therapeutic Research Area Sanofi R&D & **Fabrice ANDRE**, Inserm, Institut Gustave Roussy, Université Paris Sud, Villejuif
- Discussions around these partnerships (20 minutes) - **Moderator: Christine CHOMIENNE**, Director ITMO Cancer of Aviesan

1:20 p.m. - 3:00 p.m.

Lunch break with "poster session"

3:00 p.m. - 6:00 p.m.

B to B Meetings

6:00 p.m. - 6:30 p.m.

Last minute B to B

6:30 p.m. - 8:00 p.m.

Cocktail Reception: Bridge between International R&D Dating and International Biotechnology Dating (ARIIS/AVIESAN/BPI/LEEM)

- **Eric VIVIER**, Centre d'Immunologie de Marseille-Luminy, CNRS, Inserm, Université d'Aix-Marseille, Chief Science Officer, Senior Vice President Innate Pharma, Marseille, France
- **Dmitri WIEDERSCHAIN**, Head of Active Immunization Cluster, Immuno-Oncology Research, Sanofi, Boston